Retuximab as maintenance treatment for follicular lymphoma

Bookmark and Share
Published: 3 Aug 2010
Views: 7394
Rating:
Save
Prof Gilles Salles, Centre Hospitalier Lyon-Sud, France
Prof Gilles Salles speaks at an EHA 2010 press conference about the PRIMA study which has shown that retuximab 'maintenance' therapy after initial treatment of retuximab plus chemotherapy reduces the risk of follicular lymphoma recurrence by up to 50%. Prof Salles discusses the effects this treatment has on patients, how he expects these results to change clinical practice and his hopes for the development of further effective antibody treatments.

Related Videos

The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin...
Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florid...
The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma ( Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA )
9 Jul 2022
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly wit...
Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )
1 Jul 2022
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphom...
Dr Carol Moreno - University of Barcelona, Barcelona, Spain
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )
21 Jun 2022
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022
Ponatinib and blinatumomab shows complete molecular response for patients with P...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Jun 2022
Subcutaneous isatuximab administration in combination with pomalidomide-dexameth...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )
13 Jun 2022
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )
13 Jun 2022
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )
13 Jun 2022